A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions
Hypertension, PortalLiver Cirrhosis
Interventions
DRUG

Placebo

Placebo-matching Avenciguat

DRUG

Avenciguat

1 millligram (mg), 2 mg, or 3 mg film-coated tablet

Trial Locations (15)

1090

AKH - Medical University of Vienna, Vienna

14584

Soon Chun Hyang University Hospital Bucheon, Bucheon-si, Gyeonggi-do

28034

Hospital Ramón y Cajal, Madrid

31059

HOP Rangueil, Toulouse

48149

Universitätsklinikum Münster, Münster

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

91105

California Liver Research Institute, Pasadena

92118

HOP Beaujon, Clichy

92377

Inland Empire Clinical Trials, LLC, Rialto

100050

Beijing Friendship Hospital, Beijing

400162

"Regional Institute of Gastroenterology Hepatology Prof. Dr. O. Fodor", Cluj-Napoca

510515

NanFang Hosptial, Guangzhou

H2X 0A9

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal

215-0026

Shin-yurigaoka General Hospital, Kanagawa, Kawasaki

08035

Hospital Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY